IMNN•benzinga•
IMUNON's IMNN-001 Shows Overall Survival Benefit Across Ovarian Cancer Subgroups In Phase 2 OVATION 2 Study, With Gains In HRP And BRCA+ Patients, Favorable Safety Profile, And Simultaneous ASCO 2025 And Peer-Reviewed Publication Presentation In Gynecolog
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 3, 2025 by benzinga